Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...

Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 ...

Takeda has terminated a neuro partnership with Denali Therapeutics as the Japanese pharma undergoes a massive restructuring ...

While the opioid epidemic is one of the most urgent public health emergencies facing the U.S., new therapeutic approaches for treating the underlying substance use disorder have lagged far behind. | ...

AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI ...

The U.S. FDA and the U.K.’s Medicines and Healthcare products Regulatory Agency agreed to bolster their ongoing medical technology collaboration while also removing tariffs on British medicine exports ...

Zeto, which makes brainwave monitors for emergency rooms, received a third FDA clearance for an EEG device. The latest is ...

Newly uncloaked Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...